PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
复制标题
DOI：
10.1038/s41598-017-10925-7
复制
发表时间：
2017-08-31
影响因子：
4.6
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Zhang M;Li G;Wang Y;Wang Y;Zhao S;Haihong P;Zhao H;Wang Y
尽管许多研究已经解决了程序性细胞死亡配体1（PD-L1）表达在肺癌中的预后价值，但结果仍存在争议。对PubMed、EMBASE和科克伦图书馆数据库进行了系统检索，以确定PD-L 1表达和驱动突变与总生存期（OS）之间的相关性。本次荟萃分析共纳入47项研究的11,444例患者，汇总结果显示PD-L1表达增加与预后不良相关（HR = 1.40，95%CI：1.19-1.65，P < 0.001）。在根据组织学类型分层的亚组分析中，汇总结果表明，PD-L1表达增加是非小细胞肺癌（NSCLC）的不利预后因素（HR = 1.26，95% CI：1.05-1.52，P = 0.01）和肺淋巴上皮瘤样癌（LELC）（HR = 3.04，95%CI：1.19-7.77，P = 0.02），而非小细胞肺癌（HR = 0.62，95%CI：0.27-1.39，P = 0.24）。合并OR表明PD-L1表达与性别、吸烟状况、组织学、分化程度、肿瘤大小、淋巴结转移、TNM分期和EGFR突变相关。然而，PD-L1表达与ALK重排和KRAS突变无关。
Although many studies have addressed the prognostic value of programmed cell death-ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic search of the PubMed, EMBASE, and Cochrane Library databases was performed to identify the correlation between PD-L1 expression and driver mutations and overall survival (OS). This meta-analysis enrolled a total of 11,444 patients for 47 studies, and the pooled results showed that increased PD-L1 expression was associated with poor prognosis (HR = 1.40, 95% CI: 1.19–1.65, P < 0.001). In subgroup analysis stratified according to histology types, the pooled results demonstrated that increased PD-L1 expression was an unfavorable prognostic factor for non-small cell lung cancer (NSCLC) (HR = 1.26, 95% CI: 1.05–1.52, P = 0.01) and pulmonary lymphoepithelioma-like carcinoma (LELC) (HR = 3.04, 95% CI: 1.19–7.77, P = 0.02), rather than small cell lung cancer (SCLC) (HR = 0.62, 95% CI: 0.27–1.39, P = 0.24). The pooled ORs indicated that PD-L1 expression was associated with gender, smoking status, histology, differentiation, tumour size, lymph nodal metastasis, TNM stage and EGFR mutation. However, PD-L1 expression was not correlated with ALK rearrangement and KRAS mutations.
登录
查看更多内容
影响因子：
--
作者：
Fang W;Hong S;Chen N;He X;Zhan J;Qin T;Zhou T;Hu Z;Ma Y;Zhao Y;Tian Y;Yang Y;Xue C;Tang Y;Huang Y;Zhao H;Zhang L
通讯作者：
Zhang L
影响因子：
2.9
作者：
Guo Q;Sun Y;Yu S;Bai H;Zhao J;Zhuo M;Wang J
通讯作者：
Wang J
影响因子：
--
作者：
Chen, Yan-bin;Mu, Chuan-Yong;Huang, Jian-An
通讯作者：
Huang, Jian-An
影响因子：
50.5
作者：
Cierna, Z.;Mego, M.;Babal, P.
通讯作者：
Babal, P.
影响因子：
3.7
作者：
Ameratunga M;Asadi K;Lin X;Walkiewicz M;Murone C;Knight S;Mitchell P;Boutros P;John T
通讯作者：
John T